venclexta multiple myeloma trial, venclexta trial results, venclexta label expansion, abbvie roche venclexta, venclexta progression free survival, venclexta blood cancer, venclexta failed endpoint,

Venclexta fails to meet primary endpoint in multiple myeloma trial

Anika Sharma

AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...

CAR T-cell therapy, blood cancer treatment, immunotherapy, personalized targeting, breakthrough, benefits, risks, approved therapies, leukemia, lymphoma, multiple myeloma,

CAR T-Cell Therapy in Hematological Malignancies: A Breakthrough or a Bust?

Anika Sharma

Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes. They include leukemia, lymphoma, and multiple myeloma. ...